 | • レポートコード：MRC2-11QY13590 • 出版社/出版日：QYResearch / 2020年11月30日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、125ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は高度腎細胞癌治療薬のグローバル市場について調査・分析したレポートです。種類別（放射線療法、化学療法、ホルモン療法、治験療法）市場規模、用途別（病院、がん研究所、外来手術センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別高度腎細胞癌治療薬の競争状況、市場シェア ・世界の高度腎細胞癌治療薬市場：種類別市場規模 2015年-2020年（放射線療法、化学療法、ホルモン療法、治験療法） ・世界の高度腎細胞癌治療薬市場：種類別市場規模予測 2021年-2026年（放射線療法、化学療法、ホルモン療法、治験療法） ・世界の高度腎細胞癌治療薬市場：用途別市場規模 2015年-2020年（病院、がん研究所、外来手術センター、その他） ・世界の高度腎細胞癌治療薬市場：用途別市場規模予測 2021年-2026年（病院、がん研究所、外来手術センター、その他） ・北米の高度腎細胞癌治療薬市場分析：米国、カナダ ・ヨーロッパの高度腎細胞癌治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの高度腎細胞癌治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の高度腎細胞癌治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの高度腎細胞癌治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Acceleron Pharma、Argos Therapeutics、AVEO Pharmaceuticals、Bayer、Bristol-Myers Squibb Company、Eisai、Exelixi、Genentech、Immatics Biotechnologies、Merck、Novartis、Ono Pharmaceutical、Pfizer、Rexahn Pharmaceuticals、Hoffmann-La Roche ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Advanced renal cell carcinoma is associated with a type of kidney cancer that appears in the covering of the proximal complex tubule. The convoluted tubule is a very small part of tubes in the kidney that helps in transportation of unwanted particles from the blood to the urine. Advanced renal cell carcinoma is the most common type of kidney cancer in adults that represents nearly 2-3% of all cancer cases in adults. The disorder is asymptomatic in advanced renal cell carcinoma at initial stages that results with people often in the advanced stages of the disease by the time it is discovered. The initial symptoms of renal cell carcinoma are a general feeling of being unwell, hypertension, flank pain, weight loss, fever, blood in the urine, night sweats, and a mass in the abdomen. Management of renal cell carcinoma has seen significant development in the past few years, and new approaches are being established. Advanced renal cell carcinoma is a disease that normally cannot be treated by general therapy and is challenging to treat. Surgical removal of one or both kidneys should be considered in patients who suffer from metastatic disease before systemic therapy.
Increase in aging population is one of the major factors driving the revenue growth of the renal cell carcinoma market. Furthermore, renal cell carcinoma is a rare disease with a small patient-base constitutingall ages from infants to older adults. However, the disease is predominantly noted in age group of ~ 60-70 years, exposing a higher probability of occurrence. Expanding research into orphan drugs is a factor projected to create lucrative revenue potential for drug makers of renal cell carcinoma.
Market Analysis and Insights: Global Advanced Renal Cell Carcinoma Therapeutics Market
The global Advanced Renal Cell Carcinoma Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Advanced Renal Cell Carcinoma Therapeutics Scope and Market Size
Advanced Renal Cell Carcinoma Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Advanced Renal Cell Carcinoma Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Acceleron Pharma
Argos Therapeutics
AVEO Pharmaceuticals
Bayer
Bristol-Myers Squibb Company
Eisai
Exelixi
Genentech
Immatics Biotechnologies
Merck
Novartis
Ono Pharmaceutical
Pfizer
Rexahn Pharmaceuticals
Hoffmann-La Roche
Market segment by Type, the product can be split into
Radiation Therapy
Chemotherapy
Hormone Therapy
Investigational Therapy
Market segment by Application, split into
Hospitals
Cancer Research Institutes
Ambulatory Surgical Centers
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Advanced Renal Cell Carcinoma Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Advanced Renal Cell Carcinoma Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Radiation Therapy
1.4.3 Chemotherapy
1.4.4 Hormone Therapy
1.4.5 Investigational Therapy
1.5 Market by Application
1.5.1 Global Advanced Renal Cell Carcinoma Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Cancer Research Institutes
1.5.4 Ambulatory Surgical Centers
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Advanced Renal Cell Carcinoma Therapeutics Market Perspective (2015-2026)
2.2 Global Advanced Renal Cell Carcinoma Therapeutics Growth Trends by Regions
2.2.1 Advanced Renal Cell Carcinoma Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Advanced Renal Cell Carcinoma Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Advanced Renal Cell Carcinoma Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Advanced Renal Cell Carcinoma Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Advanced Renal Cell Carcinoma Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Advanced Renal Cell Carcinoma Therapeutics Players by Market Size
3.1.1 Global Top Advanced Renal Cell Carcinoma Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Advanced Renal Cell Carcinoma Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Advanced Renal Cell Carcinoma Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Advanced Renal Cell Carcinoma Therapeutics Market Concentration Ratio
3.2.1 Global Advanced Renal Cell Carcinoma Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Advanced Renal Cell Carcinoma Therapeutics Revenue in 2019
3.3 Advanced Renal Cell Carcinoma Therapeutics Key Players Head office and Area Served
3.4 Key Players Advanced Renal Cell Carcinoma Therapeutics Product Solution and Service
3.5 Date of Enter into Advanced Renal Cell Carcinoma Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Advanced Renal Cell Carcinoma Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Advanced Renal Cell Carcinoma Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020)
5.2 Global Advanced Renal Cell Carcinoma Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Advanced Renal Cell Carcinoma Therapeutics Market Size (2015-2020)
6.2 Advanced Renal Cell Carcinoma Therapeutics Key Players in North America (2019-2020)
6.3 North America Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020)
6.4 North America Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Advanced Renal Cell Carcinoma Therapeutics Market Size (2015-2020)
7.2 Advanced Renal Cell Carcinoma Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020)
7.4 Europe Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Advanced Renal Cell Carcinoma Therapeutics Market Size (2015-2020)
8.2 Advanced Renal Cell Carcinoma Therapeutics Key Players in China (2019-2020)
8.3 China Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020)
8.4 China Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Advanced Renal Cell Carcinoma Therapeutics Market Size (2015-2020)
9.2 Advanced Renal Cell Carcinoma Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020)
9.4 Japan Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Advanced Renal Cell Carcinoma Therapeutics Market Size (2015-2020)
10.2 Advanced Renal Cell Carcinoma Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Advanced Renal Cell Carcinoma Therapeutics Market Size (2015-2020)
11.2 Advanced Renal Cell Carcinoma Therapeutics Key Players in India (2019-2020)
11.3 India Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020)
11.4 India Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Advanced Renal Cell Carcinoma Therapeutics Market Size (2015-2020)
12.2 Advanced Renal Cell Carcinoma Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Acceleron Pharma
13.1.1 Acceleron Pharma Company Details
13.1.2 Acceleron Pharma Business Overview
13.1.3 Acceleron Pharma Advanced Renal Cell Carcinoma Therapeutics Introduction
13.1.4 Acceleron Pharma Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020))
13.1.5 Acceleron Pharma Recent Development
13.2 Argos Therapeutics
13.2.1 Argos Therapeutics Company Details
13.2.2 Argos Therapeutics Business Overview
13.2.3 Argos Therapeutics Advanced Renal Cell Carcinoma Therapeutics Introduction
13.2.4 Argos Therapeutics Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
13.2.5 Argos Therapeutics Recent Development
13.3 AVEO Pharmaceuticals
13.3.1 AVEO Pharmaceuticals Company Details
13.3.2 AVEO Pharmaceuticals Business Overview
13.3.3 AVEO Pharmaceuticals Advanced Renal Cell Carcinoma Therapeutics Introduction
13.3.4 AVEO Pharmaceuticals Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
13.3.5 AVEO Pharmaceuticals Recent Development
13.4 Bayer
13.4.1 Bayer Company Details
13.4.2 Bayer Business Overview
13.4.3 Bayer Advanced Renal Cell Carcinoma Therapeutics Introduction
13.4.4 Bayer Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
13.4.5 Bayer Recent Development
13.5 Bristol-Myers Squibb Company
13.5.1 Bristol-Myers Squibb Company Company Details
13.5.2 Bristol-Myers Squibb Company Business Overview
13.5.3 Bristol-Myers Squibb Company Advanced Renal Cell Carcinoma Therapeutics Introduction
13.5.4 Bristol-Myers Squibb Company Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
13.5.5 Bristol-Myers Squibb Company Recent Development
13.6 Eisai
13.6.1 Eisai Company Details
13.6.2 Eisai Business Overview
13.6.3 Eisai Advanced Renal Cell Carcinoma Therapeutics Introduction
13.6.4 Eisai Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
13.6.5 Eisai Recent Development
13.7 Exelixi
13.7.1 Exelixi Company Details
13.7.2 Exelixi Business Overview
13.7.3 Exelixi Advanced Renal Cell Carcinoma Therapeutics Introduction
13.7.4 Exelixi Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
13.7.5 Exelixi Recent Development
13.8 Genentech
13.8.1 Genentech Company Details
13.8.2 Genentech Business Overview
13.8.3 Genentech Advanced Renal Cell Carcinoma Therapeutics Introduction
13.8.4 Genentech Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
13.8.5 Genentech Recent Development
13.9 Immatics Biotechnologies
13.9.1 Immatics Biotechnologies Company Details
13.9.2 Immatics Biotechnologies Business Overview
13.9.3 Immatics Biotechnologies Advanced Renal Cell Carcinoma Therapeutics Introduction
13.9.4 Immatics Biotechnologies Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
13.9.5 Immatics Biotechnologies Recent Development
13.10 Merck
13.10.1 Merck Company Details
13.10.2 Merck Business Overview
13.10.3 Merck Advanced Renal Cell Carcinoma Therapeutics Introduction
13.10.4 Merck Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
13.10.5 Merck Recent Development
13.11 Novartis
10.11.1 Novartis Company Details
10.11.2 Novartis Business Overview
10.11.3 Novartis Advanced Renal Cell Carcinoma Therapeutics Introduction
10.11.4 Novartis Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
10.11.5 Novartis Recent Development
13.12 Ono Pharmaceutical
10.12.1 Ono Pharmaceutical Company Details
10.12.2 Ono Pharmaceutical Business Overview
10.12.3 Ono Pharmaceutical Advanced Renal Cell Carcinoma Therapeutics Introduction
10.12.4 Ono Pharmaceutical Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
10.12.5 Ono Pharmaceutical Recent Development
13.13 Pfizer
10.13.1 Pfizer Company Details
10.13.2 Pfizer Business Overview
10.13.3 Pfizer Advanced Renal Cell Carcinoma Therapeutics Introduction
10.13.4 Pfizer Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
10.13.5 Pfizer Recent Development
13.14 Rexahn Pharmaceuticals
10.14.1 Rexahn Pharmaceuticals Company Details
10.14.2 Rexahn Pharmaceuticals Business Overview
10.14.3 Rexahn Pharmaceuticals Advanced Renal Cell Carcinoma Therapeutics Introduction
10.14.4 Rexahn Pharmaceuticals Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
10.14.5 Rexahn Pharmaceuticals Recent Development
13.15 Hoffmann-La Roche
10.15.1 Hoffmann-La Roche Company Details
10.15.2 Hoffmann-La Roche Business Overview
10.15.3 Hoffmann-La Roche Advanced Renal Cell Carcinoma Therapeutics Introduction
10.15.4 Hoffmann-La Roche Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
10.15.5 Hoffmann-La Roche Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Advanced Renal Cell Carcinoma Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Advanced Renal Cell Carcinoma Therapeutics Revenue
Table 3. Ranking of Global Top Advanced Renal Cell Carcinoma Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Advanced Renal Cell Carcinoma Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Radiation Therapy
Table 6. Key Players of Chemotherapy
Table 7. Key Players of Hormone Therapy
Table 8. Key Players of Investigational Therapy
Table 9. Global Advanced Renal Cell Carcinoma Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Advanced Renal Cell Carcinoma Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Advanced Renal Cell Carcinoma Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Advanced Renal Cell Carcinoma Therapeutics Market Share by Regions (2015-2020)
Table 13. Global Advanced Renal Cell Carcinoma Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Advanced Renal Cell Carcinoma Therapeutics Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Advanced Renal Cell Carcinoma Therapeutics Market Growth Strategy
Table 19. Main Points Interviewed from Key Advanced Renal Cell Carcinoma Therapeutics Players
Table 20. Global Advanced Renal Cell Carcinoma Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 21. Global Advanced Renal Cell Carcinoma Therapeutics Market Share by Players (2015-2020)
Table 22. Global Top Advanced Renal Cell Carcinoma Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Advanced Renal Cell Carcinoma Therapeutics as of 2019)
Table 23. Global Advanced Renal Cell Carcinoma Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Advanced Renal Cell Carcinoma Therapeutics Product Solution and Service
Table 26. Date of Enter into Advanced Renal Cell Carcinoma Therapeutics Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 29. Global Advanced Renal Cell Carcinoma Therapeutics Market Size Share by Type (2015-2020)
Table 30. Global Advanced Renal Cell Carcinoma Therapeutics Revenue Market Share by Type (2021-2026)
Table 31. Global Advanced Renal Cell Carcinoma Therapeutics Market Size Share by Application (2015-2020)
Table 32. Global Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 33. Global Advanced Renal Cell Carcinoma Therapeutics Market Size Share by Application (2021-2026)
Table 34. North America Key Players Advanced Renal Cell Carcinoma Therapeutics Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Advanced Renal Cell Carcinoma Therapeutics Market Share (2019-2020)
Table 36. North America Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 37. North America Advanced Renal Cell Carcinoma Therapeutics Market Share by Type (2015-2020)
Table 38. North America Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 39. North America Advanced Renal Cell Carcinoma Therapeutics Market Share by Application (2015-2020)
Table 40. Europe Key Players Advanced Renal Cell Carcinoma Therapeutics Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Advanced Renal Cell Carcinoma Therapeutics Market Share (2019-2020)
Table 42. Europe Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Advanced Renal Cell Carcinoma Therapeutics Market Share by Type (2015-2020)
Table 44. Europe Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Advanced Renal Cell Carcinoma Therapeutics Market Share by Application (2015-2020)
Table 46. China Key Players Advanced Renal Cell Carcinoma Therapeutics Revenue (2019-2020) (Million US$)
Table 47. China Key Players Advanced Renal Cell Carcinoma Therapeutics Market Share (2019-2020)
Table 48. China Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 49. China Advanced Renal Cell Carcinoma Therapeutics Market Share by Type (2015-2020)
Table 50. China Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 51. China Advanced Renal Cell Carcinoma Therapeutics Market Share by Application (2015-2020)
Table 52. Japan Key Players Advanced Renal Cell Carcinoma Therapeutics Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Advanced Renal Cell Carcinoma Therapeutics Market Share (2019-2020)
Table 54. Japan Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Advanced Renal Cell Carcinoma Therapeutics Market Share by Type (2015-2020)
Table 56. Japan Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Advanced Renal Cell Carcinoma Therapeutics Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Advanced Renal Cell Carcinoma Therapeutics Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Advanced Renal Cell Carcinoma Therapeutics Market Share (2019-2020)
Table 60. Southeast Asia Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Advanced Renal Cell Carcinoma Therapeutics Market Share by Type (2015-2020)
Table 62. Southeast Asia Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Advanced Renal Cell Carcinoma Therapeutics Market Share by Application (2015-2020)
Table 64. India Key Players Advanced Renal Cell Carcinoma Therapeutics Revenue (2019-2020) (Million US$)
Table 65. India Key Players Advanced Renal Cell Carcinoma Therapeutics Market Share (2019-2020)
Table 66. India Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 67. India Advanced Renal Cell Carcinoma Therapeutics Market Share by Type (2015-2020)
Table 68. India Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 69. India Advanced Renal Cell Carcinoma Therapeutics Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Advanced Renal Cell Carcinoma Therapeutics Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Advanced Renal Cell Carcinoma Therapeutics Market Share (2019-2020)
Table 72. Central & South America Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Advanced Renal Cell Carcinoma Therapeutics Market Share by Type (2015-2020)
Table 74. Central & South America Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Advanced Renal Cell Carcinoma Therapeutics Market Share by Application (2015-2020)
Table 76. Acceleron Pharma Company Details
Table 77. Acceleron Pharma Business Overview
Table 78. Acceleron Pharma Product
Table 79. Acceleron Pharma Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020) (Million US$)
Table 80. Acceleron Pharma Recent Development
Table 81. Argos Therapeutics Company Details
Table 82. Argos Therapeutics Business Overview
Table 83. Argos Therapeutics Product
Table 84. Argos Therapeutics Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020) (Million US$)
Table 85. Argos Therapeutics Recent Development
Table 86. AVEO Pharmaceuticals Company Details
Table 87. AVEO Pharmaceuticals Business Overview
Table 88. AVEO Pharmaceuticals Product
Table 89. AVEO Pharmaceuticals Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020) (Million US$)
Table 90. AVEO Pharmaceuticals Recent Development
Table 91. Bayer Company Details
Table 92. Bayer Business Overview
Table 93. Bayer Product
Table 94. Bayer Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020) (Million US$)
Table 95. Bayer Recent Development
Table 96. Bristol-Myers Squibb Company Company Details
Table 97. Bristol-Myers Squibb Company Business Overview
Table 98. Bristol-Myers Squibb Company Product
Table 99. Bristol-Myers Squibb Company Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020) (Million US$)
Table 100. Bristol-Myers Squibb Company Recent Development
Table 101. Eisai Company Details
Table 102. Eisai Business Overview
Table 103. Eisai Product
Table 104. Eisai Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020) (Million US$)
Table 105. Eisai Recent Development
Table 106. Exelixi Company Details
Table 107. Exelixi Business Overview
Table 108. Exelixi Product
Table 109. Exelixi Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020) (Million US$)
Table 110. Exelixi Recent Development
Table 111. Genentech Business Overview
Table 112. Genentech Product
Table 113. Genentech Company Details
Table 114. Genentech Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020) (Million US$)
Table 115. Genentech Recent Development
Table 116. Immatics Biotechnologies Company Details
Table 117. Immatics Biotechnologies Business Overview
Table 118. Immatics Biotechnologies Product
Table 119. Immatics Biotechnologies Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020) (Million US$)
Table 120. Immatics Biotechnologies Recent Development
Table 121. Merck Company Details
Table 122. Merck Business Overview
Table 123. Merck Product
Table 124. Merck Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020) (Million US$)
Table 125. Merck Recent Development
Table 126. Novartis Company Details
Table 127. Novartis Business Overview
Table 128. Novartis Product
Table 129. Novartis Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020) (Million US$)
Table 130. Novartis Recent Development
Table 131. Ono Pharmaceutical Company Details
Table 132. Ono Pharmaceutical Business Overview
Table 133. Ono Pharmaceutical Product
Table 134. Ono Pharmaceutical Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020) (Million US$)
Table 135. Ono Pharmaceutical Recent Development
Table 136. Pfizer Company Details
Table 137. Pfizer Business Overview
Table 138. Pfizer Product
Table 139. Pfizer Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020) (Million US$)
Table 140. Pfizer Recent Development
Table 141. Rexahn Pharmaceuticals Company Details
Table 142. Rexahn Pharmaceuticals Business Overview
Table 143. Rexahn Pharmaceuticals Product
Table 144. Rexahn Pharmaceuticals Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020) (Million US$)
Table 145. Rexahn Pharmaceuticals Recent Development
Table 146. Hoffmann-La Roche Company Details
Table 147. Hoffmann-La Roche Business Overview
Table 148. Hoffmann-La Roche Product
Table 149. Hoffmann-La Roche Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020) (Million US$)
Table 150. Hoffmann-La Roche Recent Development
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Advanced Renal Cell Carcinoma Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Radiation Therapy Features
Figure 3. Chemotherapy Features
Figure 4. Hormone Therapy Features
Figure 5. Investigational Therapy Features
Figure 6. Global Advanced Renal Cell Carcinoma Therapeutics Market Share by Application: 2020 VS 2026
Figure 7. Hospitals Case Studies
Figure 8. Cancer Research Institutes Case Studies
Figure 9. Ambulatory Surgical Centers Case Studies
Figure 10. Others Case Studies
Figure 11. Advanced Renal Cell Carcinoma Therapeutics Report Years Considered
Figure 12. Global Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Advanced Renal Cell Carcinoma Therapeutics Market Share by Regions: 2020 VS 2026
Figure 14. Global Advanced Renal Cell Carcinoma Therapeutics Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Advanced Renal Cell Carcinoma Therapeutics Market Share by Players in 2019
Figure 17. Global Top Advanced Renal Cell Carcinoma Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Advanced Renal Cell Carcinoma Therapeutics as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Advanced Renal Cell Carcinoma Therapeutics Revenue in 2019
Figure 19. North America Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Bottom-up and Top-down Approaches for This Report
Figure 27. Data Triangulation
Figure 28. Key Executives Interviewed
基底細胞がん（BCC）治療薬の世界市場（～2026年） Basal Cell Carcinoma (BCC) is a form of non-melanocytic skin cancer that arises from basal cells, the small, round cells present in the lower epidermis. Around 85% of BCCs occur on the face, head and neck. BCCs usually do not spread or metastasize to other parts of body, they become life threatening…- 腎細胞がん治療薬の世界市場（～2026年） Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases.The drug is …
- 腎細胞癌治療薬の世界市場（～2026年） Market Analysis and Insights: Global Renal Cell Cacinoma Drugs Market The global Renal Cell Cacinoma Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Renal Cell Cacinoma Drugs Scope and Market Size Renal Cell Caci…
- ナチュラルキラー細胞療法の世界市場（～2026年） Cell therapy, a new therapeutic approach that uses a patient's own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body's first line of defense against infections and diseases with an innate ability to rapidly seek and destr…
- がん幹細胞治療の世界市場（～2026年） Market Analysis and Insights: Global Cancer Stem Cell Therapy Market The global Cancer Stem Cell Therapy market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Cancer Stem Cell Therapy Scope and Market Size Cancer Stem Cell T…